Aureon Laboratories, Inc.
HCID Member | Biotech Specialty Pharma  Advamed Member
28 Wells Avenue
Yonkers, NY 10701 USA
phone: 914.377.4000
fax: 914.377.4001
Symbol Private
Founded 2001
Employees
www.aureon.com
Research Sector Biotech Specialty Pharma
Summary Description
Predictive clinical tests for cancer care and bio-pharmaceutical research and development.
Management
Vijay Aggarwal, PhD, CEO & President; Charles J. Di Como, PhD, Director of Laboratories; Peter Duncan, VP Business Development; Ricardo Mesa-Tejada, MD, VP, Pathology & Medical Director; Robert Shovlin, COO; Michael J. Donovan, MD, PhD, SVP, Research Collaborations; Derek Tranzillo, Director, Finance & Administration
Keywords
predictive clinical test, cancer, prostate cancer, post-Urology, prostate, urinary, bladder, erectilectomy, urology, advamed, j2008

Comment | Printable Version | Sept. 15, 2008
If you work for Aureon Laboratories, Inc. and want to update this profile, click here

Description
Aureon Laboratories' mission is to enable personalized patient care through predictive pathology. It is a privately-held organization applying its 'systems pathology' technology to develop tests for cancer care and facilitate bio-pharmaceutical research and development.
Products / Services
Using patient biopsy tissue, Prostate Px (R) predicts the extent of prostate cancer progression and the likelihood of prostate cancer recurrence post-surgery, which enables patients and physicians to devise the appropriate methods of treatment. Specifically, Aureon's technology platform generates and analyzes an integrated, digital view of clinical findings, tissue micro-anatomy and tissue molecular pathology to determine which combination of features predicts specified individual clinical outcomes.
Technology / Differentiation
The basis for the predictive power of Prostate Px (R) is Aureon's proprietary systems pathology platform, comprised of several elements. First, the Aureon PathoMetrix (TM) is an automated "machine vision tissue image analysis system" that uses advanced image processing algorithms to segment and measure notable histological and/or pathological elements. The features extracted from the images are then integrated with clinical and molecular information to assess disease severity and to predict disease progression; this can provide a more objective alternative to the current diagnostic system (Gleason scores) used by pathologists. Next, the M-Plex(TM) fluorescently tags individual antibodies and analyzes the antigen-antibody complexes of interest utilizing spectral imaging. Finally, Aureon has ventured into the domain of artificial intelligence with its Discovery-Path (TM) technology, which uses multivariate analysis to "learn" from patients' data and improves the ability of physicians to provide accurate prognoses.
Market / Customers
According to The American Cancer Society, there will be approximately 186,320 new cases of prostate cancer and 28,660 deaths from this disease in the United States by the end of 2008. Prostate cancer is the second leading cause of cancer death in men, behind lung cancer. Prostate Px(R) is intended for men at low-to-intermediate risk; this group represents most of the newly diagnosed cases.
Status
Aureon introduced Prostate Px (R) in May 2008 at the American Urological Association's annual meeting. The company recently announced its collaborative research endeavor with the University of Texas M.D. Anderson Cancer Center, which will apply Aureon's systems pathology platform in the analysis of non-small cell lung cancer (NSCLC) tissue. The goal of the study is to quantify and evaluate biomarkers associated with disease progression and survival.


2008-11-23-1996